- Home
- DYAI vs IMMX Comparison
DYAI vs IMMX Comparison
Compare DYAI & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- IMMX
- Stock Information
- Founded
- DYAI 1979
- IMMX 2014
- Country
- DYAI United States
- IMMX United States
- Employees
- DYAI N/A
- IMMX N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- DYAI Health Care
- IMMX Health Care
- Exchange
- DYAI Nasdaq
- IMMX Nasdaq
- Market Cap
- DYAI 54.4M
- IMMX 50.1M
- IPO Year
- DYAI 2004
- IMMX 2021
- Fundamental
- Price
- DYAI $1.21
- IMMX $1.71
- Analyst Decision
- DYAI Strong Buy
- IMMX Strong Buy
- Analyst Count
- DYAI 1
- IMMX 1
- Target Price
- DYAI $6.00
- IMMX $7.00
- AVG Volume (30 Days)
- DYAI 25.3K
- IMMX 41.7K
- Earning Date
- DYAI 05-13-2025
- IMMX 05-08-2025
- Dividend Yield
- DYAI N/A
- IMMX N/A
- EPS Growth
- DYAI N/A
- IMMX N/A
- EPS
- DYAI N/A
- IMMX N/A
- Revenue
- DYAI $3,495,389.00
- IMMX N/A
- Revenue This Year
- DYAI $117.40
- IMMX N/A
- Revenue Next Year
- DYAI N/A
- IMMX N/A
- P/E Ratio
- DYAI N/A
- IMMX N/A
- Revenue Growth
- DYAI 20.58
- IMMX N/A
- 52 Week Low
- DYAI $0.93
- IMMX $1.26
- 52 Week High
- DYAI $2.67
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- DYAI 39.42
- IMMX 53.28
- Support Level
- DYAI $1.20
- IMMX $1.61
- Resistance Level
- DYAI $1.29
- IMMX $1.57
- Average True Range (ATR)
- DYAI 0.07
- IMMX 0.15
- MACD
- DYAI 0.00
- IMMX 0.02
- Stochastic Oscillator
- DYAI 18.52
- IMMX 82.37
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.